探索linagliptin在骨髓瘤细胞系中用于抗癌活性的分子机制
Asiye Gok Yurttas1, Mustafa Fatih Dasci2
1Department of Biochemistry, Faculty of Pharmacy, Istanbul Health and Technology University, Istanbul, Turkey.
Pathology, research and practice
|July 8, 2023
概括
林格利普丁 (LG) 有效地抑制骨髓瘤细胞生长,并诱导细胞死亡. 这项研究探讨了LG LG.
科学领域:
- 在瘤学瘤学.
- 药理学 药理学是指药理学的学科.
- 分子生物学分子生物学
背景情况:
- 重新利用现有药物为新型抗癌剂的发现提供了一个快速的战略.
- 骨髓瘤 (OS) 是一种主要的骨癌,治疗导致显著的发病率.
- 在SAOS-2细胞中研究林格利普丁 (LG) 对抗OS活性至关重要.
研究的目的:
- 系统地评估林格利普丁 (LG) 对骨髓瘤的抗癌作用.
- 为了确定LG对Saos-2细胞活力和亡的影响.
- 阐明LG在骨髓瘤中的作用背后的分子机制.
主要方法:
- 使用MTT测试评估的细胞活力.
- 通过流细胞计评估的亡.
- 通过qPCR阵列进行基因表达分析,以分析癌症途径.
主要成果:
- 林加利普丁显著降低了Saos-2和hFOB1.19细胞活力 (p < 0.001).
- 在SAOS-2 (p < 0.001) 和hFOB1.19 (p < 0.05) 细胞中,LG治疗显著增加了细胞灭亡.
- qPCR分析揭示了LG对癌症相关基因表达的影响.
结论:
- 利纳格利普丁显示强烈抑制骨髓瘤细胞增殖.
- 在骨髓瘤细胞中,LG有效诱导编程细胞死亡 (亡).
- 通过降低癌症途径中的关键基因的调节,LG发挥其作用.
关键词:
这是一种抗癌药物.在HFOB1.19中,我们可以看到HFOB1.19的位置.林纳格利普丁 (Linagliptin) 是一种药物.骨质肉瘤骨质肉瘤是什么这是一个QPCRR.这就是Saos-2的意义.更多相关视频
08:47Improved Visualization of Lung Metastases at Single Cell Resolution in Mice by Combined In-situ Perfusion of Lung Tissue and X-Gal Staining of lacZ-Tagged Tumor Cells
Published on: August 21, 2012
17.4K
08:04Cytotoxic Efficacy of Photodynamic Therapy in Osteosarcoma Cells In Vitro
Published on: March 18, 2014
12.9K
相关概念视频
03:03mTOR Signaling and Cancer Progression
3.8K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...
3.8K
01:23Dipeptidyl Peptidase 4 Inhibitors
214
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
214